NEW YORK, April 11, 2023 /PRNewswire/ -- The obsessive-compulsive disorder drugs market size is forecast to increase by USD 266.78 million from 2021 to 2026, at a CAGR of 5.55%, according to the recent market study by Technavio. The growth of the market will be driven by the rising prevalence of OCD, the launch of new molecules, and awareness programs for OCD. Technavio offers an up-to-date analysis of the current global market scenario and the overall market environment. View Sample Report

Technavio categorizes the global obsessive-compulsive disorder drugs market Vendor Analysis:

The global OCD market is fragmented due to the presence of numerous generic as well as branded drugs. Technavio has extensively analyzed 15 major vendors, including AbbVie Inc., Apotex Inc., Biohaven Pharmaceutical Holding Co. Ltd., Dr. Reddys Laboratories Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H Lundbeck AS, Jazz Pharmaceuticals Plc, Lannett Co. Inc., Lupin Ltd., Mallinckrodt Plc, Novartis AG, Omeros Corp., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Viatris Inc.

Vendor Offerings -

• AbbVie Inc. - The company offers VRAYLAR which is a prescription medicine used in adults for the treatment of obsessive-compulsive disorder.

• Apotex Inc. - The company offers Paroxetine tablets that are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder as defined in the DSM-IV.

• Biohaven Pharmaceutical Holding Co. Ltd. - The company offers Troriluzole that modulates glutamate in an effort to reduce the severity of anxiety, worry, and functional impairment of people with anxiety.

Charts & data tables about market and segment sizes during the forecast period (2022-
2026) have been covered in this report. Download The Sample Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.

• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.

• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Get a holistic overview of the endoscopic closure devices market by industry experts to
evaluate and develop growth strategies. Download the Sample

Obsessive-Compulsive Disorder Drugs Market - Market Segmentation:

This report extensively covers obsessive-compulsive disorder drugs market segmentation by product (SSRI, TSA, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

• The market share growth by the SSRI segment will be significant for the market growth during the forecast period. The market's expansion is fueled by the abundance of SSRIs like fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram. Due to the high demand for SSRIs, numerous generic versions have been approved by significant nations and organizations, including the United States, the European Union (EU), and Japan. SSRIs with controlled release and sustained release are being developed by some businesses. During the forecast period, the market for these new drugs is expected to grow quickly.

Obsessive-Compulsive Disorder Drugs Market - Market Dynamics:

Key DRIVERS:

• A key factor driving growth in the obsessive-compulsive disorder drugs market is the rising prevalence of OCD.

• OCD is a mental illness that lasts a long time and is chronic. Due to individuals' drastic lifestyle shifts, OCD is prevalent in high-income nations.

• For instance, people are more likely to be influenced by fictitious images, intrusive thoughts, and urges when they are exposed to movie technologies. In high-income nations, OCD is ranked as the fourth most common mental illness.

• Men, women, and children all suffer from OCD. In the early stages of childhood, adolescence, or adulthood, it is most obvious. Over the forecast period, the market is anticipated to be driven by the disorder's high prevalence.

Major Trends:

• The rising use of off-label therapies is obsessive-compulsive disorder drugs market trend that is expected to have a positive impact during the forecast period.

• Prescription pharmacological treatments for OCD include off-label treatments from a variety of drug classes as well as several approved treatments.

• Off-label treatments like vortioxetine, duloxetine, esketamine, aripiprazole, duloxetine, vortioxetine, and risperidone are available despite the fact that the OCD drug market is dominated by approved treatments.

• Off-label treatments include vortioxetine, duloxetine, esketamine, and aripiprazole. Due to relapse and refractory to first-line therapies, many OCD treatment guidelines recommend using off-label therapies as second-line treatments.

• The utilization of off-name treatments will probably increment in the OCD drugs market over the forecast period because of the absence of improvement of new treatments.

Key Challenges:

• The difficulties in diagnosing OCD will be a major challenge hampering the obsessive-compulsive disorder drugs market during the forecast period.

• OCD is moderately a typical problem, however viable treatment is accessible, nonetheless, it is frequently underdiagnosed and undertreated by doctors because of the absence of evidential side effects.

• The OCD side effects might shift from people due to the non-revelation mindset of the patients, underneath recorded are a few troubles for doctors to analyze the OCD.

• Absent signs: Due to an inferiority complex and a lack of awareness, patients frequently conceal their symptoms and do not seek assistance. Repeated questioning, difficulty making decisions or completing them, procrastination, and constantly seeking assurance are some of the symptoms.

• OCD has become a major challenge to identify because it is difficult to distinguish it from other psychiatric disorders because most of them share similar symptoms.

To get detailed insights about inclusions and exclusions, buy the report 

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this Obsessive-Compulsive Disorder Drugs Market report?

• CAGR of the market during the forecast period

• Detailed information on factors that will drive the growth of the Obsessive-Compulsive Disorder Drugs Market between 2022 and 2026

• Precise estimation of the size of the Obsessive-Compulsive Disorder Drugs Market and its contribution to the parent market

• Accurate predictions about upcoming trends and changes in consumer behavior

• Growth of the Obsessive-Compulsive Disorder Drugs Market across North America, Europe, Asia, and Rest of World (ROW)

• A thorough analysis of the market's competitive landscape and detailed information about vendors

• Comprehensive analysis of factors that will challenge the growth of Obsessive-Compulsive Disorder Drugs Market vendors

Related Reports:

The central nervous system disorders therapeutics market size is expected to increase by USD 24.35 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 4.44%. The report extensively covers central nervous system disorders therapeutics market segmentation by type (depression drugs, multiple sclerosis drugs, schizophrenia drugs, bipolar disorder therapeutics, epilepsy drugs, and others) and geography (Europe, North America, Asia, and ROW). The increasing prevalence of CNS disorders is notably driving the central nervous system disorders therapeutics market growth.

According to Technavio's analyst, the dementia and movement disorder treatment market size is expected to be valued at USD 7.14 billion by 2026 with a progressing CAGR of 6.95%. This report further entails dementia and movement disorder treatment market segmentations, including drug class (MAO inhibitors, acetylcholinesterase inhibitors, glutamate inhibitors, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The growing geriatric population is notably driving dementia and movement disorder treatment market growth.

Browse for Technavio's Health Care Market Reports  

Table of contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition

• 3.2 Market segment analysis

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026

4 Five Forces Analysis

• 4.1 Five forces summary

• 4.2 Bargaining power of buyers

• 4.3 Bargaining power of suppliers

• 4.4 Threat of new entrants

• 4.5 Threat of substitutes

• 4.6 Threat of rivalry

• 4.7 Market condition

5 Market Segmentation by Product

• 5.1 Market segments

• 5.2 Comparison by Product

• 5.3 SSRI - Market size and forecast 2021-2026

• 5.4 TSA - Market size and forecast 2021-2026

• 5.5 Others - Market size and forecast 2021-2026

• 5.6 Market opportunity by Product

6 Customer Landscape

• 6.1 Customer landscape overview

7 Geographic Landscape

• 7.1 Geographic segmentation

• 7.2 Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026

• 7.4 Europe - Market size and forecast 2021-2026

• 7.5 Asia - Market size and forecast 2021-2026

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026

• 7.7 US - Market size and forecast 2021-2026

• 7.8 Germany - Market size and forecast 2021-2026

• 7.9 UK - Market size and forecast 2021-2026

• 7.10 France - Market size and forecast 2021-2026

• 7.11 Canada - Market size and forecast 2021-2026

• 7.12 Market opportunity by geography

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape

• 9.3 Landscape disruption

• 9.4 Industry risks

10 Vendor Analysis

• 10.1 Vendors covered

• 10.2 Market positioning of vendors

• 10.3 AbbVie Inc.

• 10.4 Apotex Inc.

• 10.5 Biohaven Pharmaceutical Holding Co. Ltd.

• 10.6 Dr. Reddys Laboratories Ltd.

• 10.7 Eli Lilly and Co.

• 10.8 GlaxoSmithKline Plc

• 10.9 H Lundbeck AS

• 10.10 Jazz Pharmaceuticals Plc

• 10.11 Novartis AG

• 10.12 Pfizer Inc.

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist

• 11.3 Currency conversion rates for US$

• 11.4 Research methodology

• 11.5 List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/obsessive-compulsive-disorder-drugs-market-size-to-grow-by-usd-266-78-million-from-2021-to-2026--driven-by-the-rising-prevalence-of-ocd---technavio-301793218.html

SOURCE Infiniti Research, Inc.